APSR2026-939

 
Late-Breaking
Submitted
Poster Presentation
 
AP02-022
P30
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1220368-46904-APSR_Poster_A0_Reza_432725.pdf
Format: PDF Only
05. Respiratory Infections (non-tuberculous)
6

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Reza Permana Putra * Faculty of Medicine Lampung University Department of Pulmonology and Respiratory Medicine Bandar Lampung Indonesia
Adhari Ajipurnomo - Faculty of Medicine Lampung University Department of Pulmonology and Respiratory Medicine Bandar Lampung Indonesia
Mohammad Junus Didiek Herdato - Faculty of Medicine Lampung University Department of Pulmonology and Respiratory Medicine Bandar Lampung Indonesia
Andreas Infianto - Faculty of Medicine Lampung University Department of Pulmonology and Respiratory Medicine Bandar Lampung Indonesia
Pad Dilangga - Faculty of Medicine Lampung University Department of Pulmonology and Respiratory Medicine Bandar Lampung Indonesia
Gigih Setiawan - Faculty of Medicine Lampung University Department of Pulmonology and Respiratory Medicine Bandar Lampung Indonesia
 
 
 
 
 
 
 
 
 
Presenting Author Details
Reza Permana
Putra
rezapermanap@gmail.com
+6282133355545
31-40
Indonesia
Original Research
Low-dose azithromycin significantly reduces IL-6 levels in moderate pneumonia: a comparative clinical study
Maximum 25 words
Abstract Content
Excessive systemic inflammation drives disease progression in pneumonia, with interleukin-6 (IL-6) serving as a key prognostic biomarker. Targeting inflammatory pathways may improve outcomes beyond antimicrobial effects. Azithromycin has known immunomodulatory properties, yet its impact on IL-6 in acute moderate pneumonia remains underexplored. This study aimed to determine whether low-dose azithromycin reduces IL-6 levels when added to empirical therapy.
This comparative clinical experimental study included 30 hospitalized patients with moderate pneumonia at Dr. Abdul Moeloek Hospital, Indonesia (2025–2026). Patients were consecutively allocated into two groups: empirical therapy plus low-dose azithromycin and empirical therapy alone. Serum IL-6 levels were measured before and after treatment. Within-group changes were analyzed using the paired t-test, and between-group differences were assessed using the independent t-test. Statistical significance was set at p < 0.05.
Baseline characteristics were comparable between groups (p > 0.05). In the azithromycin group, mean IL-6 levels decreased markedly from 65.59 ± 19.19 pg/mL to 24.40 ± 6.71 pg/mL (p < 0.001). In the control group, IL-6 levels decreased from 60.27 ± 13.59 pg/mL to 40.83 ± 10.72 pg/mL (p = 0.001). The magnitude of IL-6 reduction was significantly greater in the azithromycin group compared with controls (−41.19 ± 13.37 vs −19.43 ± 4.94; p < 0.001).
Adjunct low-dose azithromycin produces a significantly greater reduction in IL-6 levels compared with standard empirical therapy alone. These findings support its immunomodulatory role in attenuating systemic inflammation in moderate pneumonia.
 
 
 
 
 
Yes
Yes
https://storage.unitedwebnetwork.com/files/1285/1220368-37089-APSR1_398131.png
JPG or JPEG or PNG format ONLY
interleukin-6, pneumonia, azithromycin, inflammation, immunomodulation
maximum 3 keywords and no abbreviations, separated by commas
Acknowledgement The authors would like to thank the staff of the Department of Pulmonology and Respiratory Medicine and the Clinical Pathology Laboratory of Dr. Abdul Moeloek Hospital, Lampung, Indonesia, for their support during data collection and laboratory analysis. Disclosure Statement The authors declare no conflict of interest. This study was self-funded by the investigators.
244